PT1564293E - Expressão génica de proteínas de filamento neural e detecção de doença de alzheimer - Google Patents

Expressão génica de proteínas de filamento neural e detecção de doença de alzheimer Download PDF

Info

Publication number
PT1564293E
PT1564293E PT04076254T PT04076254T PT1564293E PT 1564293 E PT1564293 E PT 1564293E PT 04076254 T PT04076254 T PT 04076254T PT 04076254 T PT04076254 T PT 04076254T PT 1564293 E PT1564293 E PT 1564293E
Authority
PT
Portugal
Prior art keywords
neural thread
alzheimer
disease
detection
gene expression
Prior art date
Application number
PT04076254T
Other languages
English (en)
Portuguese (pt)
Inventor
Jack R Wands
Suzanne M De La Monte
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Publication of PT1564293E publication Critical patent/PT1564293E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/474—Pancreatic thread protein; Reg protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Physics & Mathematics (AREA)
PT04076254T 1993-04-20 1994-04-20 Expressão génica de proteínas de filamento neural e detecção de doença de alzheimer PT1564293E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5055993A 1993-04-20 1993-04-20

Publications (1)

Publication Number Publication Date
PT1564293E true PT1564293E (pt) 2008-12-02

Family

ID=21965952

Family Applications (1)

Application Number Title Priority Date Filing Date
PT04076254T PT1564293E (pt) 1993-04-20 1994-04-20 Expressão génica de proteínas de filamento neural e detecção de doença de alzheimer

Country Status (11)

Country Link
EP (2) EP1564293B9 (enExample)
JP (2) JP3513859B2 (enExample)
KR (1) KR100392244B1 (enExample)
AT (2) ATE406444T1 (enExample)
CA (1) CA2161097A1 (enExample)
DE (2) DE69435136D1 (enExample)
DK (2) DK0697893T3 (enExample)
ES (2) ES2255054T3 (enExample)
NZ (1) NZ266072A (enExample)
PT (1) PT1564293E (enExample)
WO (1) WO1994023756A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US5936078A (en) * 1995-12-12 1999-08-10 Kyowa Hakko Kogyo Co., Ltd. DNA and protein for the diagnosis and treatment of Alzheimer's disease
AU1110297A (en) * 1995-12-12 1997-07-03 Kyowa Hakko Kogyo Co. Ltd. Novel dnas, novel polypeptides and novel antibodies
AU749348B2 (en) 1997-02-26 2002-06-27 General Hospital Corporation, The Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's disease
US7226730B1 (en) 1997-02-26 2007-06-05 The General Hospital Corporation Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's Disease
JP2001514663A (ja) 1997-03-12 2001-09-11 エスモンド,ロバート ダブリュー. アルツハイマー病を処置または予防するための方法
EP1541166B1 (en) * 2001-05-16 2007-12-19 Nymox Corporation Preventing cell death using segments of neural thread proteins
JP2004529179A (ja) 2001-05-16 2004-09-24 ナイモックス コーポレーション 神経線維タンパク質のセグメントを使用する細胞死の予防法
US6770797B2 (en) 2001-06-01 2004-08-03 Rhode Island Hospital Non-Transgenic nonhuman model for Alzheimer's Disease using a AD7c-NTP nucleic acid
EP1714979A3 (en) * 2001-11-16 2007-04-25 Nymox Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
US7317077B2 (en) 2001-11-16 2008-01-08 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
PL1994152T3 (pl) * 2006-02-28 2013-05-31 Nymox Corp Peptydy skuteczne w leczeniu nowotworów i innych stanów wymagających usunięcia lub zniszczenia komórek
US20080027005A1 (en) * 2006-07-31 2008-01-31 Paul Averback Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
US11628202B2 (en) 2015-07-24 2023-04-18 Nymox Corporation Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia
US10183058B2 (en) 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US10172910B2 (en) 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
US10335453B2 (en) 2017-03-01 2019-07-02 Nymox Corporation Compositions and methods for improving sexual function
JP2025516554A (ja) * 2022-05-10 2025-05-30 エフ. ホフマン-ラ ロシュ アーゲー Cfp-elk1遺伝子間領域を標的とするアンチセンスオリゴヌクレオチド
WO2024227045A1 (en) * 2023-04-27 2024-10-31 Siemens Healthcare Diagnostics Inc. High-sensitivity assay for serum neurofilament light chain cross reference to related applications

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0378924B1 (en) * 1988-12-21 1996-11-13 The General Hospital Corporation Detection of neurological disease or dysfunction

Also Published As

Publication number Publication date
EP1564293A1 (en) 2005-08-17
EP0697893B1 (en) 2005-12-07
JP3513859B2 (ja) 2004-03-31
ES2255054T3 (es) 2006-06-16
EP1564293B9 (en) 2009-08-19
EP0697893A4 (en) 1996-12-18
JP2004097227A (ja) 2004-04-02
EP0697893A1 (en) 1996-02-28
AU6666994A (en) 1994-11-08
ES2312913T3 (es) 2009-03-01
WO1994023756A1 (en) 1994-10-27
AU674581B2 (en) 1997-01-02
DE69434844D1 (de) 2006-10-19
DE69435136D1 (de) 2008-10-09
DE69434844T2 (de) 2006-12-14
DK0697893T3 (da) 2006-02-20
EP1564293B1 (en) 2008-08-27
DK1564293T3 (da) 2009-01-12
ATE312348T1 (de) 2005-12-15
JPH08509808A (ja) 1996-10-15
KR100392244B1 (ko) 2003-11-28
CA2161097A1 (en) 1994-10-27
NZ266072A (en) 1997-07-27
ATE406444T1 (de) 2008-09-15

Similar Documents

Publication Publication Date Title
ATE312348T1 (de) Geneexpression der neurofilamentproteine und nachweis der alzheimeschen erkrankung
DE69735375D1 (de) Genfamilie von apoptose-verwandten peptiden, dadurch kodierte peptide und verfahren zu deren herstellung
EP0442961A4 (en) Hybrid procoagulant proteins
ATE365744T1 (de) Nukleinsäuremoleküle, proteine und peptide, die im zusammenhang stehen mit dickdarmzellen und dickdarm-krebszellen
PT939804E (pt) Neutroquina alfa
ZA91134B (en) New proteins produced by human lymphocytes,dna sequence encoding these proteins and their pharmaceutical and biological uses
EP1439230A3 (en) Human transmembrane protein TMP-2 gene
NZ279963A (en) Human tissue inhibitor of metalloproteinase-4 (timp-4) and dna (rna) encoding polypeptide which may be derived from atcc 75946
DE69430818D1 (de) Pns-dns-pns-chimäre makromoleküle
DE69632536D1 (de) Impfstoffe für das respiratorische-synzytial-virus mit nuklein säuren
SE8106641L (sv) Hybrida humanleukocytinterferoner
DE3684295D1 (de) Antigene proteine und diese enthaltende impfstoffe zur verhuetung von kokzidiose.
EP1015477A4 (en) 32 PROTEINS SPILLED BY HUMANS
KR970705635A (ko) 사람 케모킨 베타-9(Human chemokine beta-9)
EP0837130A3 (en) M protein analogue from Streptococcus pneumoniae
EP0826774A3 (en) Staphylococcal Fab I enoyl-ACP reductase
NZ242955A (en) Dna containing gene sequences corresponding to sequences causing alzheimers disease, detection, recombinant yeast with such code
KR860006484A (ko) 단백질 또는 당단백질의 제조방법
EP0845535A3 (en) Leader peptidase (lep) from Streptococcus
AU5315790A (en) Molecules containing at least one peptide sequence carrying one or several epitopes characteristic of a protein produced by p. falciparum at the sporozoite stage and in the hepatocytes
PT990000E (pt) Factor 3 de crescimento do tecido conjuntivo
NO962596L (no) Nytt tumorsupressorgen
EP0839910A3 (en) Spo-rel, a Staphylococcus relA/spot homologue
EP0723016A3 (en) Leukocyte activation factor
WO1996027015A3 (en) A novel gene for a protein kinase associated with drug resistance